Hikal Ltd., a long-term partner for global life sciences companies, has announced its audited financial results for the quarter and year ending 31st March 2026. The company’s revenue for Q4 FY26 was recorded at ₹ 519 crore, with an EBITDA of ₹ 105 crore, representing a margin of 20.3%. The company also reported a profit after tax (PAT) of ₹ 14 crore for the quarter.
Hikal’s board has approved a final dividend of 20% of the face value, contributing to a total dividend of 30% for the year. The company’s long-term credit rating remains stable at A, as assessed by ICRA.
For the full fiscal year FY26, Hikal reported a revenue of ₹ 1,713 crore with an EBITDA margin of 12.9%. The pharmaceutical segment showed a significant recovery, with H2 FY26 revenue growing by 60% to ₹ 629 crore compared to H1 FY26. The crop protection segment also demonstrated strong performance, with Q4 revenues increasing 45% quarter-on-quarter to ₹ 228 crore, and a 13% year-on-year growth.
Hikal’s strategic diversification into personal care and specialty chemicals is gaining traction, with commercialization expected in upcoming quarters. The company has maintained balance sheet discipline, focusing on improving operating cash flow and return on capital employed.
Jai Hiremath, Executive Chairman of Hikal Ltd., commented on the results, highlighting the company’s transition from remediation to sustainable growth. He noted that the strategic investments in high-potency laboratories and pilot plants are now operational, strengthening Hikal’s position in complex chemistries.
The company continues to expand its CDMO pipeline, supported by increasing outsourcing opportunities. Hikal is also enhancing its capabilities in animal health, focusing on high-value, innovation-led opportunities.
Looking ahead, Hikal aims to improve its product mix, expand the CDMO pipeline, and diversify into higher-value segments. The company expects new products in these areas to contribute significantly from FY27 onwards.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).